68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)
J.W. Valle, S. Qin, L. Antonuzzo, D. Tougeron, CK Lee, B.J. Tan, M. Ikeda, V. Guthrie, P. McCoon, Y.S. Lee, N. Rokutanda, M. Żotkiewicz, G. Cohen, D-Y. Oh
Topics & Concepts
MedicineDurvalumabGemcitabineBiliary tract cancerCisplatinPlaceboInternal medicineOncologyCancerChemotherapyPathologyImmunotherapyNivolumabAlternative medicineCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersPeptidase Inhibition and Analysis